FDA Extends Review for Rhythm’s Obesity Drug Imcivree to March 2026

Rhythm Pharmaceuticals announced that the FDA has extended the review of its obesity drug Imcivree for acquired hypothalamic obesity by three months, moving the decision date to March 20, 2026.